Business Context and Reporting Period
This Form 8-K Current Report, filed on April 4, 2017, covers events occurring on March 31, 2017, for AIT Therapeutics, Inc., a Delaware corporation. The filing discloses the completion of a private placement of equity securities and the entry into a material definitive agreement with private investors.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $663,000 (before fees and expenses).
- Securities Issued: 110,494 Units.
- Unit Composition: Each Unit consists of one share of Common Stock and warrants to purchase two shares of Common Stock.
- Purchase Price: $6.00 per Unit.
- Warrant Terms: Exercise price of $6.90 per share with a five-year term; includes cashless exercise provisions if a registration statement is not effective.
- Liquidity Impact: The transaction provides immediate capital to the Company, though specific cash flow statements or debt levels are not detailed in this filing.
Material Changes and Agreements
The primary material change is the issuance of unregistered equity securities under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. The Company entered into a Stock Purchase and Registration Rights Agreement requiring the filing of a registration statement for the resale of the securities. The filing deadline is set as two weeks following the effectiveness of the Company's Form S-1 (File No. 333-216287).
Guidance, Risks, and Contingencies
The filing outlines significant financial contingencies tied to the Company's ability to register the securities for resale:
- Penalty for Registration Failure: If the Company fails to file the Registration Statement by the deadline or fails to have it declared effective by the "Effectiveness Deadline," it must pay investors 1.5% of their aggregate investment monthly until cured, capped at 19.5% of the total purchase price.
- Uncapped Penalty: In specific instances of registration-related failures, the penalty increases to 3.0% of the aggregate purchase price per month with no cap.
- Reporting Obligations: The Company must maintain the effectiveness of the Registration Statement until all securities are sold or Rule 144 restrictions are lifted.
- Management Commentary: No forward-looking guidance or operational outlook is provided in this specific filing beyond the transaction details.
Investor Verification Checklist
- Verify the effectiveness status of the Company's Form S-1 (File No. 333-216287) to determine the specific Registration Statement filing deadline.
- Confirm the Company's current compliance with Exchange Act reporting obligations to avoid triggering uncapped penalty payments.
- Review the full text of the Stock Purchase and Registration Rights Agreement (Exhibit 10.1) for detailed terms regarding the "Effectiveness Deadline."
- Assess the dilution impact of the 110,494 Units and the associated 220,988 warrant shares on existing shareholders.